enGene Therapeutics (ENGN) Income towards Parent Company (2023 - 2026)

enGene Therapeutics (ENGN) has reported Income towards Parent Company for 4 consecutive years, with -$30.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Income towards Parent Company fell 17.09% year-over-year to -$30.2 million; the TTM figure through Apr 2026 stood at -$23.1 million (up 71.05% YoY), while the FY2025 annual figure was -$13.6 million, up 75.38% from the prior year.
• Income towards Parent Company eased to -$30.2 million in Q2 2026 per ENGN's latest filing, from -$29.8 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $65.8 million in Q4 2025 and bottomed at -$82.5 million in Q4 2023.
• Historically, Income towards Parent Company has averaged -$16.3 million across 4 years, with a median of -$15.1 million in 2024.
• Annual changes were most pronounced in 2024 — Income towards Parent Company sank 199.75% — and 2025, when it jumped 530.4%.
• enGene Therapeutics' Income towards Parent Company stood at -$82.5 million in 2023, then surged by 81.46% to -$15.3 million in 2024, then surged by 530.4% to $65.8 million in 2025, then tumbled by 145.9% to -$30.2 million in 2026.
• Business Quant data shows ENGN's Income towards Parent Company at -$30.2 million in Q2 2026, -$29.8 million in Q1 2026, and $65.8 million in Q4 2025.